Advisor Group’s Theriva Biologics TOVX Stock Holding History

Advisor Group’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	2	–	–	﹤0.01%	5445
2019 Q3	$0	Hold	2	–	–	﹤0.01%	5419
2019 Q2	$0	Hold	2	–	–	﹤0.01%	5358
2019 Q1	$0	Buy	+2	New	+$331	﹤0.01%	5328
2017 Q3	–	Hold	0	–	–	–	4942
2017 Q2	–	Hold	0	–	–	–	4908
2017 Q1	–	Hold	0	–	–	–	4800
2016 Q4	–	Hold	0	–	–	–	4616
2016 Q3	–	Hold	0	–	–	–	4611
2016 Q2	–	Hold	0	–	–	–	4500

Other funds holding TOVX

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

SCA

Snowden Capital Advisors New York $4.23B AUM 29.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Advisor Group's TOVX Position: Q4 2019 in Review

Advisor Group held its Theriva Biologics (TOVX) position steady in Q4 2019 at 2 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5445.

Advisor Group first reported a position in TOVX in Q1 2019 and has held it in 4 quarters since. 17 funds tracked by Wall St. Rank hold TOVX as of Q4 2019.

Advisor Group held 2 shares of Theriva Biologics worth $0 as of Q4 2019.
Advisor Group left its Theriva Biologics share count unchanged in Q4 2019.
Theriva Biologics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5445 holding.
Advisor Group first reported a position in Theriva Biologics in Q1 2019 and has held it in 4 quarters since.
17 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.